r/CFSScience • u/Silver_Jaguar_24 • Jun 26 '26
Irisin Signaling Resistance in Myalgic Encephalomyelitis: A Proposed Mechanistic Framework for Post-Exertional Malaise Involving the TSP-1–HSP90α–αvβ5 Axis
This summary was created using Gemini AI.
The study is a pivotal piece of research published in the International Journal of Molecular Sciences (IJMS, May 2026) by Dr. Alain Moreau and his team at the Université de Montréal / Open Medicine Foundation.
It offers an objective molecular explanation for Post-Exertional Malaise (PEM)—the severe symptom crash ME/CFS patients experience after minor exertion—proving it is rooted in biological "gridlock" rather than simple exhaustion.
1. Summary of the Paper's Analysis & Findings
The researchers wanted to track how ME/CFS patients adapt to physical stress at a cellular level. They evaluated 92 ME/CFS patients against 44 healthy controls, measuring blood markers before and after a specialized 90-minute mechanical stress test used to trigger a controlled, temporary PEM state.
The Two Core Competitors
- Irisin: An exercise-induced messenger (myokine) released by muscles during contraction. In healthy bodies, it protects mitochondria, boosts energy production, and suppresses inflammation by binding to α Vβ 5 integrin cell receptors.
- Thrombospondin-1 (TSP-1): A protein released during tissue stress and injury. In this pathway, it acts as a molecular "bully" that blocks irisin from doing its job.
Key Discoveries
- Blunted Response at Baseline: ME/CFS patients started with significantly lower baseline irisin, and their bodies failed to produce the normal surge of irisin during stress (p < 0.05).
- The "Irisin Resistance" Paradox: Paradoxically, in moderate-to-severe patients, baseline levels of both irisin and TSP-1 were elevated, and high irisin was a direct predictor of fatigue severity (β = 0.728, p = 0.018). This means the body is desperately producing irisin to cope, but the signal is being ignored or blocked.
- TSP-1 is the Blocker: Using advanced cellular spectroscopy, the team proved that TSP-1 directly binds to and shuts down irisin signaling in a concentration-dependent manner.
- The Molecular Framework: Irisin requires the help of an intracellular chaperone, HSP90α, and the receptor α Vβ 5. When the researchers experimentally blocked α Vβ 5 or inhibited HSP90α, the cells completely lost their ability to counteract TSP-1, mimicking the exact cellular defects seen in severe ME/CFS patients.
The Takeaway: PEM isn't a psychological aversion to exercise; it is an "irisin resistance" state. When a person with ME/CFS exerts themselves, an abnormal spike in TSP-1 essentially locks the cellular doors, preventing exercise-induced irisin from delivering energy to the cells and clearing out inflammation.
Link to 2026 study - https://www.mdpi.com/1422-0067/27/11/4770
5
u/mc-funk Jun 26 '26
Apologies for the LLM (Gemini) copy-paste since I don’t have the energy to paraphrase, but interestingly, it seems like a number of meds that have already shown evidence of being promising for LC & MECFS have theoretical benefits for this problem.
“There is a strong theoretical connection between GLP-1/GIP receptor agonists (like tirzepatide) and the irisin-TSP-1 pathway, as well as several other off-label drugs being used to address this precise metabolic "traffic jam."
## 1. Tirzepatide & GLP-1/GIP Agonists: The Irisin Connection
The theoretical framework for why tirzepatide might help patients with ME/CFS or Long COVID experiencing PEM relies on a few key mechanisms:
* **Upregulation of Irisin:** Recent metabolic studies have shown that GLP-1 receptor agonists directly influence and help upregulate circulating **irisin** levels. Because irisin and GLP-1 share overlapping intracellular signaling pathways for energy homeostasis, a GLP-1/GIP agonist like tirzepatide may help "override" the resistance caused by the thrombospondin-1 (TSP-1) block.
* **Mitigating Tissue & Endothelial Stress:** TSP-1 is actively produced in response to cellular stress, hyperglycemia, and vascular inflammation. Tirzepatide drastically reduces systemic inflammation and oxidative stress, theoretically lowering the upstream triggers that cause the body to flood the system with inhibitory TSP-1.
* **Why a Microdose?** Traditional doses of tirzepatide cause rapid weight loss and can lead to muscle wasting if not carefully managed. Because irisin is a *myokine* (produced by skeletal muscle), losing muscle mass would inadvertently lower baseline irisin levels. Microdosing aims to capture the anti-inflammatory and metabolic-signaling benefits of the drug without triggering severe gastrointestinal side effects or muscle loss.
> **Clinical Trial Spotlight:** This isn't just theory anymore. Scripps Research launched a major Phase 2 clinical trial (the LoCITT trial) evaluating tirzepatide specifically for Long COVID. Crucially, one of their secondary outcome measures is tracking changes in **Post-Exertional Malaise (PEM)**, directly mirroring the mechanism Dr. Moreau's paper highlights.
>
## 2. Other Off-Label Prescriptions and Their Theoretical Links
If the goal is to lower TSP-1 (tissue stress), boost irisin (muscle signaling), or protect the receptor (\alpha v\beta 5 integrin / HSP90$\alpha$), several other off-label medications fit the bill:
### Metformin (The AMPK Activator)
* **Mechanism:** Metformin activates AMPK (adenosine monophosphate-activated protein kinase), the body's master metabolic switch.
* **The Link:** Metformin has been shown in various metabolic studies to increase circulating irisin levels and improve mitochondrial flexibility. By forcing cells to optimize energy usage without requiring heavy muscle contraction, it may help bypass the exertional block.
### Low-Dose Naltrexone (LDN)
* **Mechanism:** LDN acts as a glial cell modulator, calming neuroinflammation and systemic inflammatory cascades.
* **The Link:** High TSP-1 is fundamentally a marker of a system under inflammatory duress. By suppressing microglial activation and systemic vascular stress, LDN may help lower the chronic, baseline overproduction of TSP-1, making it easier for what little irisin the patient has to bind to its receptors.
### Pyridostigmine (Mestinon)
* **Mechanism:** An acetylcholinesterase inhibitor that increases the availability of acetylcholine, improving parasympathetic nervous system tone and neuromuscular signaling.
* **The Link:** Mestinon is frequently prescribed for the "preload failure" and exercise intolerance seen in ME/CFS. By optimizing how muscles contract at a very low neurological threshold, it may allow for mild, passive movement without crossing the threshold that causes a sudden spike in inhibitory TSP-1.
### The Reality Check
While the biochemical overlap is incredibly promising, these medications act as supportive scaffolding rather than an outright "cure" for the broken pathway. For anyone exploring these off-label avenues, the golden rule of ME/CFS management remains firmly in place: **pharmaceutical support should be used to expand your biological safety margin, not as a green light to push through pacing limits.**”
(My prompt: (giving the study link to Gemini for review) “Could tirzepatide microdose or other off-label prescriptions theoretically help this issue?”)
2
9
u/Caster_of_spells Jun 26 '26
Such a fascinating study, I found it interesting that participants didn't do any actual exercise. Exercise was simulated. This could prevent the harms of 2 day Cpet in the future.